semaglutide diarrhea class action in michigan law firm Ozempic Lawsuit FDA warns consumers not to – Ozempic, weight-loss drugs face backlash

News A new study finds lowered risk of 42 health outcomes and increased risk of 19 for people using GLP-1RAs, highlighting the far-reaching potential of the drugs

Less than 5% body weight loss after 16 or more weeks at a therapeutic dose (10mg or above) constitutes a poor response

Personal medical history should be discussed with a healthcare provider to assess risk

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance

It has been associated with a reduction in major cardiovascular events, such as heart attack and stroke, in patients with type 2 diabetes and cardiovascular disease